Inovio Pharmaceuticals (INO) EPS (Weighted Average and Diluted) (2016 - 2025)
Inovio Pharmaceuticals (INO) has disclosed EPS (Weighted Average and Diluted) for 14 consecutive years, with $0.31 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 151.67% to $0.31 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.68 through Dec 2025, up 57.89% year-over-year, with the annual reading at -$1.81 for FY2025, 54.18% up from the prior year.
- EPS (Weighted Average and Diluted) hit $0.31 in Q4 2025 for Inovio Pharmaceuticals, up from -$0.87 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.31 in Q4 2025 to a low of -$16.5 in Q4 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.16 across 5 years, with a median of -$0.74 in 2025.
- Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 14900.0% in 2021 and later surged 151.67% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$16.5 in 2021, then rose by 20.55% to -$13.11 in 2022, then surged by 91.76% to -$1.08 in 2023, then surged by 44.44% to -$0.6 in 2024, then soared by 151.67% to $0.31 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for INO at $0.31 in Q4 2025, -$0.87 in Q3 2025, and -$0.61 in Q2 2025.